Overview

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
To compare the effects and safety of Anlotinib Plus Irinotecan versus Irinotecan in patients with esophageal squamous cell carcinoma(ESCC).
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Treatments:
Irinotecan